Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis

[1]  E. Ward,et al.  Expression of the Tyrosine Phosphatase Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase 1 Determines T Cell Activation Threshold and Severity of Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.

[2]  P. Christadoss,et al.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. , 2002, The Journal of clinical investigation.

[3]  P. Christadoss,et al.  Role of IL-5 during primary and secondary immune response to acetylcholine receptor , 2002, Journal of Neuroimmunology.

[4]  K. Coggeshall,et al.  Visualization of Negative Signaling in B Cells by Quantitative Confocal Microscopy , 2001, Molecular and Cellular Biology.

[5]  P. Christadoss,et al.  Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR , 2000, Journal of Neuroimmunology.

[6]  F. Shi,et al.  Natural killer cells determine the outcome of B cell–mediated autoimmunity , 2000, Nature Immunology.

[7]  F. Beermann,et al.  Impaired Natural Killing of MHC Class I-Deficient Targets by NK Cells Expressing a Catalytically Inactive Form of SHP-11 , 2000, The Journal of Immunology.

[8]  K. Siminovitch,et al.  Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. , 2000, Seminars in immunology.

[9]  U. Lorenz,et al.  The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. , 1999, International immunology.

[10]  K. Siminovitch,et al.  Involvement of the SHP-1 tyrosine phosphatase in regulation of T cell selection. , 1999, Journal of immunology.

[11]  P. Allen,et al.  Cutting edge: the tyrosine phosphatase SHP-1 regulates thymocyte positive selection. , 1999, Journal of immunology.

[12]  H. Link,et al.  Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. , 1999, Journal of immunology.

[13]  L. Borysiewicz,et al.  TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. , 1999, Journal of immunology.

[14]  P. Christadoss,et al.  The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. , 1998, Journal of immunology.

[15]  G. Comi,et al.  IL‐12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody‐ mediated disease , 1998, European journal of immunology.

[16]  D. Wylie,et al.  DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance. , 1997, Journal of immunology.

[17]  P. Christadoss,et al.  Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. , 1997, Journal of immunology.

[18]  P. Christadoss,et al.  Interferon γ (IFN-γ) Is Necessary for the Genesis of Acetylcholine Receptor–induced Clinical Experimental Autoimmune Myasthenia gravis in Mice , 1997, The Journal of experimental medicine.

[19]  K. Tomita,et al.  Abnormal development and differentiation of macrophages and dendritic cells in viable motheaten mutant mice deficient in haematopoietic cell phosphatase , 1997, International journal of experimental pathology.

[20]  D. Greiner,et al.  Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. , 1997, Trends in biotechnology.

[21]  T. Yi,et al.  Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. , 1997, Experimental hematology.

[22]  L. Shultz,et al.  Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. , 1997, Experimental hematology.

[23]  K. Ravichandran,et al.  Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Siminovitch,et al.  Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase , 1996, The Journal of experimental medicine.

[25]  E. Shevach,et al.  IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. , 1996, Immunology today.

[26]  G. Wu,et al.  B and T cells are not required for the viable motheaten phenotype , 1996, The Journal of experimental medicine.

[27]  D. Fearon,et al.  A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. , 1995, Science.

[28]  G. Trinchieri,et al.  B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation , 1994, The Journal of experimental medicine.

[29]  T. Pawson,et al.  Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice , 1993, The Journal of experimental medicine.

[30]  D. Sgroi,et al.  CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. , 1993, The Journal of biological chemistry.

[31]  D. Fearon,et al.  CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. , 1992, Science.

[32]  D. Sgroi,et al.  The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2–6 sialyltransferase, CD75, on B cells , 1991, Cell.

[33]  B. Mcmaster,et al.  CD19 is functionally and physically associated with surface immunoglobulin , 1989, The Journal of experimental medicine.

[34]  E. Sercarz,et al.  Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. , 1989, Cellular immunology.

[35]  J. D. Marshall,et al.  Murine "viable motheaten" mutation reveals a gene critical to the development of both B and T lymphocytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Shultz,et al.  Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev). , 1989, Experimental hematology.

[37]  D. Greiner,et al.  Defective lymphopoiesis in the bone marrow of motheaten (me/me) and viable motheaten (mev/mev) mutant mice. III. Normal mouse bone marrow cells enable mev/mev prothymocytes to generate thymocytes after intravenous transfer , 1987, The Journal of experimental medicine.

[38]  D. Greiner,et al.  Defective lymphopoiesis in the bone marrow of motheaten (me/me) and viable motheaten (mev/mev) mutant mice. II. Description of a microenvironmental defect for the generation of terminal deoxynucleotidyltransferase-positive bone marrow cells in vitro. , 1987, Journal of immunology.

[39]  R. Hardy,et al.  Production of immunoglobulin isotypes by Ly-1+ B cells in viable motheaten and normal mice. , 1986, Science.

[40]  L. Shultz,et al.  "Viable motheaten," a new allele at the motheaten locus. I. Pathology. , 1984, The American journal of pathology.

[41]  E. Clark,et al.  Mutations in mice that influence natural killer (NK) cell activity , 1981, Immunogenetics.

[42]  E. Unanue,et al.  The mouse mutant "motheaten." II. Functional studies of the immune system. , 1978, Journal of immunology.

[43]  E. Unanue,et al.  The mouse mutant "motheaten". I. Development of lymphocyte populations. , 1978, Journal of immunology.

[44]  L. Shultz,et al.  Motheaten, an immunodeficient mutant of the mouse. II. Depressed immune competence and elevated serum immunoglobulins. , 1976, Journal of immunology.

[45]  L. Shultz,et al.  Motheaten, an immunodeficient mutant of the mouse. I. Genetics and pathology. , 1975, The Journal of heredity.

[46]  R. Coffman,et al.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. , 1989, Annual review of immunology.